In one clinical study (NCT02410733), the mRNA vaccine (BNT111) encoding four TAAs (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE) was evaluated in patients bearing advanced melanoma. This evidence concerns the gene MAGEA3 and melanoma.